Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
1979 1
1980 1
1981 1
1984 3
1985 1
1986 1
1988 4
1989 2
1990 2
1991 5
1992 2
1993 3
1994 1
1995 1
1996 5
1997 4
1998 4
1999 9
2000 8
2001 7
2002 7
2003 4
2004 7
2005 5
2006 10
2007 7
2008 11
2009 7
2010 12
2011 9
2012 12
2013 7
2014 13
2015 8
2016 8
2017 6
2018 9
2019 7
2020 12
2021 14
2022 15
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Adrenal Gland Pheochromocytoma"
Page 1
Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Nölting S, et al. Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019. Endocr Rev. 2022. PMID: 34147030 Free PMC article. Review.
Krebs cycle/VHL/EPAS1-related cluster 1 tumors tend to a noradrenergic biochemical phenotype and require very close follow-up due to the risk of metastasis and recurrence. In contrast, kinase signaling-related cluster 2 tumors are characterized by an adrenergic phenotype a …
Krebs cycle/VHL/EPAS1-related cluster 1 tumors tend to a noradrenergic biochemical phenotype and require very close follow-up due to the ris …
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L. Wachtel H, et al. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4661-70. doi: 10.1210/clinem/dgaa608. J Clin Endocrinol Metab. 2020. PMID: 32877928 Free PMC article.
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP) are scoring systems to predict metastatic potential in pheochromocytomas (PCC) and paragan …
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Phe …
Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
Li M, Prodanov T, Meuter L, Kerstens MN, Bechmann N, Prejbisz A, Remde H, Timmers HJLM, Nölting S, Talvacchio S, Berends AMA, Fliedner S, Robledo M, Lenders JWM, Pacak K, Eisenhofer G, Pamporaki C. Li M, et al. J Clin Endocrinol Metab. 2023 Jan 17;108(2):397-404. doi: 10.1210/clinem/dgac563. J Clin Endocrinol Metab. 2023. PMID: 36190922 Free PMC article.
CONTEXT: Long-term follow-up has been recommended for patients with pheochromocytoma or paraganglioma (PPGL) due to potential for recurrent disease. However, the need to follow patients with sporadic PPGL has recently become controversial. OBJECTIVE: To investigate …
CONTEXT: Long-term follow-up has been recommended for patients with pheochromocytoma or paraganglioma (PPGL) due to potential for …
Malignant adrenal tumors.
Rescorla FJ. Rescorla FJ. Semin Pediatr Surg. 2006 Feb;15(1):48-56. doi: 10.1053/j.sempedsurg.2005.11.008. Semin Pediatr Surg. 2006. PMID: 16458846 Review.
Adrenal tumors, apart from neuroblastoma, are relatively rare in infancy and childhood. ...The two main malignant tumors are adrenocortical carcinoma and pheochromocytoma. In both tumors, it may be difficult to determine benign from malignant and the biologic behavi …
Adrenal tumors, apart from neuroblastoma, are relatively rare in infancy and childhood. ...The two main malignant tumors are adrenoco …
Pheochromocytoma.
Ram CV. Ram CV. Cardiol Clin. 1988 Nov;6(4):517-35. Cardiol Clin. 1988. PMID: 3067844 Review.
Fortunately, more than 90 per cent of all pheochromocytomas originate in the adrenal gland, but the tumor can occur at any site in the sympathetic chain. ...An understanding of the pathophysiology and natural course is vital to the rational management of pati …
Fortunately, more than 90 per cent of all pheochromocytomas originate in the adrenal gland, but the tumor can occur at any sit …
Genotype-Phenotype Correlations and Clinical Outcomes in 155 Cases of Pheochromocytoma and Paraganglioma.
Wang H, Papachristos AJ, Gill AJ, Clifton-Bligh R, Aniss AM, Glover A, Sywak M, Sidhu SB. Wang H, et al. World J Surg. 2023 Mar;47(3):690-698. doi: 10.1007/s00268-022-06862-w. Epub 2022 Dec 22. World J Surg. 2023. PMID: 36550325
BACKGROUND: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours, often associated with germline mutations that influence the disease biology and clinical course. ...Mutation presence was associated with younger age, smaller tumour size and bila …
BACKGROUND: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours, often associated with germline mutations that …
SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
Su T, Yang Y, Jiang L, Xie J, Zhong X, Wu L, Jiang Y, Zhang C, Zhou W, Ye L, Ning G, Wang W. Su T, et al. Front Endocrinol (Lausanne). 2023 Mar 16;14:1121397. doi: 10.3389/fendo.2023.1121397. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37008946 Free PMC article.
Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and metastasis. This study aimed to clarify the potential effect of SDHB IHC as a predictive mark …
Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closel …
Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas.
Araujo-Castro M, García Sanz I, Mínguez Ojeda C, Hanzu F, Mora M, Vicente A, Blanco Carrera C, de Miguel Novoa P, López García MDC, Lamas C, Manjón-Miguélez L, Del Castillo Tous M, Rodríguez de Vera P, Barahona San Millán R, Recasens M, Tomé Fernández-Ladreda M, Valdés N, Gracia Gimeno P, Robles Lazaro C, Michalopoulou T, Álvarez Escolá C, García Centeno R, Barca-Tierno V, Herrera-Martínez AD, Calatayud M. Araujo-Castro M, et al. Front Endocrinol (Lausanne). 2023 Dec 7;14:1279828. doi: 10.3389/fendo.2023.1279828. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38155946 Free PMC article.
PURPOSE: To evaluate the rate of recurrence among patients with pheochromocytomas and sympathetic paragangliomas (PGLs; together PPGLs) and to identify predictors of recurrence (local recurrence and/or metastatic disease). ...After a median follow-up o …
PURPOSE: To evaluate the rate of recurrence among patients with pheochromocytomas and sympathetic paragangliomas (PGLs; together PPGL …
Pheochromocytoma and paraganglioma: imaging characteristics.
Baez JC, Jagannathan JP, Krajewski K, O'Regan K, Zukotynski K, Kulke M, Ramaiya NH. Baez JC, et al. Cancer Imaging. 2012 May 7;12(1):153-62. doi: 10.1102/1470-7330.2012.0016. Cancer Imaging. 2012. PMID: 22571874 Free PMC article. Review.
The accurate diagnosis of adult pheochromocytoma and paraganglioma necessitates a multidisciplinary approach that includes clinical history, biochemical testing, and multimodality imaging such as computed tomography, magnetic resonance imaging, and nuclear medicine studies …
The accurate diagnosis of adult pheochromocytoma and paraganglioma necessitates a multidisciplinary approach that includes clinical h …
Clinical differences between small and large pheochromocytomas and paragangliomas.
Zhao L, Li Z, Meng X, Fan H, Zhang Z, Zhang Z, Liu Y, Zhou X, Zhu H. Zhao L, et al. Front Endocrinol (Lausanne). 2023 Mar 9;14:1087506. doi: 10.3389/fendo.2023.1087506. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36967797 Free PMC article.
Taking above variables into the same model, the area under the receiver operating characteristic curve of the model for predicting the large tumor was 0.772 (95% CI: 0.706-0.834). After the short-term follow-up, there was no significant difference in tumor recurrence …
Taking above variables into the same model, the area under the receiver operating characteristic curve of the model for predicting th …
242 results